Altimmune Inc (ALT)
7.20
+0.12
(+1.69%)
USD |
NASDAQ |
Apr 25, 16:00
7.20
0.00 (0.00%)
After-Hours: 07:33
Altimmune Cash from Financing (TTM): 86.10M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 86.10M |
September 30, 2023 | 13.31M |
June 30, 2023 | 44.78M |
March 31, 2023 | 53.30M |
December 31, 2022 | 56.78M |
September 30, 2022 | 69.36M |
June 30, 2022 | 37.42M |
March 31, 2022 | 33.86M |
December 31, 2021 | 65.10M |
September 30, 2021 | 75.27M |
June 30, 2021 | 211.29M |
March 31, 2021 | 247.81M |
December 31, 2020 | 213.49M |
September 30, 2020 | 190.83M |
June 30, 2020 | 54.63M |
March 31, 2020 | -0.0703M |
December 31, 2019 | 12.53M |
September 30, 2019 | 44.01M |
June 30, 2019 | 48.47M |
March 31, 2019 | 45.17M |
December 31, 2018 | 32.49M |
September 30, 2018 | 0.9714M |
June 30, 2018 | 9.547M |
March 31, 2018 | 12.81M |
December 31, 2017 | 15.84M |
Date | Value |
---|---|
September 30, 2017 | 15.15M |
June 30, 2017 | 4.221M |
March 31, 2017 | 8.014M |
December 31, 2016 | 4.982M |
September 30, 2016 | 5.704M |
June 30, 2016 | 3.961M |
March 31, 2016 | 0.4111M |
December 31, 2015 | 0.2231M |
September 30, 2015 | 2.744M |
June 30, 2015 | 12.93M |
March 31, 2015 | 15.19M |
December 31, 2014 | 16.73M |
September 30, 2014 | 14.97M |
June 30, 2014 | 5.316M |
March 31, 2014 | 6.468M |
December 31, 2013 | 5.030M |
September 30, 2013 | 4.360M |
June 30, 2013 | 4.728M |
March 31, 2013 | 0.4551M |
December 31, 2012 | 3.720M |
September 30, 2012 | 3.629M |
June 30, 2012 | 2.373M |
March 31, 2012 | 8.973M |
December 31, 2011 | 5.781M |
September 30, 2011 | 21.63M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.0703M
Minimum
Mar 2020
247.81M
Maximum
Mar 2021
82.01M
Average
54.63M
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
Eli Lilly and Co | 3.496B |
Amgen Inc | 21.05B |
Viking Therapeutics Inc | 873.23M |
Precision BioSciences Inc | 5.387M |
Terns Pharmaceuticals Inc | 41.95M |